Article: Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis.
2023 Volume 11, Page(s) 1154518
Abstract: Background: Preterm infants born between 33 and 35 weeks of gestational age (wGA) have been considered a "major underserved population" and ineligible to receive palivizumab (PLV), the only drug authorized to date for respiratory syncytial virus (RSV) ... ...
| Abstract | Background: Preterm infants born between 33 and 35 weeks of gestational age (wGA) have been considered a "major underserved population" and ineligible to receive palivizumab (PLV), the only drug authorized to date for respiratory syncytial virus (RSV) prophylaxis, by current international guidelines. In Italy, such a vulnerable population is currently eligible for prophylaxis, and, in our region, specific risk factors are taken into consideration (SIN Materials and methods: A retrospective analysis was conducted in 296 moderate-to-late preterm infants (born between 33 and 35 Results: Based on the SIN Conclusion: Our work further supports the need for targeting late preterm infants for RSV prophylaxis and calls for an appraisal of the current eligibility criteria for PLV treatment. Therefore, adopting less restrictive criteria may ensure a comprehensive prophylaxis of the eligible subjects, thus sparing them from avoidable short- and long-term consequences of RSV infection. |
|---|---|
| Language | English |
| Publishing date | 2023-06-08 |
| Publishing country | Switzerland |
| Document type | Journal Article |
| ZDB-ID | 2711999-3 |
| ISSN | 2296-2360 |
| ISSN | 2296-2360 |
| DOI | 10.3389/fped.2023.1154518 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.